Literature DB >> 11753543

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis.

J P Klein1, J D Rizzo, M J Zhang, N Keiding.   

Abstract

In this paper, we describe modern statistical methods for presentation of the results of studies of bone marrow transplantation. We focus here on 'univariate' or unadjusted techniques to describe the outcomes of such studies. In another paper we will discuss multivariate methods. We discuss the type of data one may have available to make inference about outcomes. We explain the differences between the Kaplan-Meier estimator of the survival function and the cumulative incidence curve, how these curves should be interpreted and when each is the appropriate summary statistic. We discuss the weighted log rank statistic and show how different weights can be used to put emphasis on detecting differences between groups in different time periods. We also present a simple estimate of current leukemia-free survival which is useful in summarizing post-transplant events.

Entities:  

Mesh:

Year:  2001        PMID: 11753543     DOI: 10.1038/sj.bmt.1703260

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  53 in total

1.  Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.

Authors:  Koen van Besien; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Lucy A Godley; Peter H O'Donnell; Justin Kline; Vu Nguyen; Paula Del Cerro; Richard A Larson; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-09       Impact factor: 5.742

2.  Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Authors:  Junya Kanda; David A Rizzieri; Cristina Gasparetto; Gwynn D Long; John P Chute; Keith M Sullivan; Ashley Morris; Clayton A Smith; Donna E Hogge; Janet Nitta; Kevin Song; Donna Niedzwiecki; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-22       Impact factor: 5.742

3.  Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation.

Authors:  Junya Kanda
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490

4.  Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data).

Authors:  Yoshiko Atsuta
Journal:  Int J Hematol       Date:  2015-11-07       Impact factor: 2.490

5.  Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation.

Authors:  Kanako Wakahashi; Motohiro Yamamori; Kentaro Minagawa; Shinichi Ishii; Shinichirou Nishikawa; Manabu Shimoyama; Hiroki Kawano; Yuko Kawano; Yuriko Kawamori; Akiko Sada; Toshimitsu Matsui; Yoshio Katayama
Journal:  Int J Hematol       Date:  2011-07-14       Impact factor: 2.490

6.  Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Rodrigo Martino; Rocio Parody; Takahiro Fukuda; Johan Maertens; Koen Theunissen; Aloysius Ho; Ghulam J Mufti; Nicolaus Kroger; Arnold R Zander; Dominik Heim; Monika Paluszewska; Dominik Selleslag; Katerina Steinerova; Per Ljungman; Simone Cesaro; Anna Nihtinen; Catherine Cordonnier; Lourdes Vazquez; Monica López-Duarte; Javier Lopez; Rafael Cabrera; Montserrat Rovira; Stefan Neuburger; Oliver Cornely; Ann E Hunter; Kieren A Marr; Hans Jürgen Dornbusch; Hermann Einsele
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

7.  Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.

Authors:  Charles Craddock; Sandeep Nagra; Andrew Peniket; Cassandra Brookes; Laura Buckley; Emmanouil Nikolousis; Nick Duncan; Sudhir Tauro; John Yin; Effie Liakopoulou; Panos Kottaridis; John Snowden; Donald Milligan; Gordon Cook; Eleni Tholouli; Tim Littlewood; Karl Peggs; Paresh Vyas; Fiona Clark; Mark Cook; Stephen Mackinnon; Nigel Russell
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

8.  Modeling cumulative incidence function for competing risks data.

Authors:  Mei-Jie Zhang; Xu Zhang; Thomas H Scheike
Journal:  Expert Rev Clin Pharmacol       Date:  2008-05-01       Impact factor: 5.045

9.  Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.

Authors:  S R Solomon; C A Sizemore; X Zhang; S Brown; H K Holland; L E Morris; A Bashey
Journal:  Bone Marrow Transplant       Date:  2014-05       Impact factor: 5.483

10.  Statistical analysis of arthroplasty register data.

Authors:  Jonas Ranstam; Otto Robertsson
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.